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Agitated behavior constitutes up to 10% of emergency psychiatric interventions. Pharma-
cological tranquilization is often used as a valid treatment for agitation but a strong evidence
base does not underpin it. Available literature shows different recommendations, supported
by research data, theoretical considerations, or clinical experience. Rapid tranquilization (RT)
is mainly based on parenteral drug treatment and the few existing guidelines on this topic,
when suggesting the use of first generation antipsychotics and benzodiazepines, include
drugs with questionable tolerability profile such as chlorpromazine, haloperidol, midazolam,
and lorazepam. In order to systematically evaluate safety concerns related to the adoption
of such guidelines, we reviewed them independently from principal diagnosis while exam-
ining tolerability data for suggested treatments. There is a growing evidence about safety
profile of second generation antipsychotics for RT but further controlled studies providing
definitive data in this area are urgently needed.
Keywords: psychomotor agitation, rapid tranquilization, treatment guidelines, safety, tolerability, parenteral
treatment, torsade de pointe, respiratory depression
INTRODUCTION
Agitated behavior constitutes up to 10% of emergency psychiatric
interventions (Tardiff and Sweillam, 1982). The overall prevalence
of agitation in patients with schizophrenia or mood disorder is
about 11–13%, with even higher rates among individuals with
alcoholism (25%) or substance misuse (35%) (Swanson et al.,
1990), dementia (24–45%), anxiety disorders (20–30%).
Agitation has rarely been the primary focus of both phenom-
enological classification and therapeutic intervention. In addition
the study of agitation in mental illness has been complicated by a
host of often imprecise or conflicting definitions (Mintzer, 2006).
Available evidences indicate an extreme variability in the manage-
ment of agitation cases in emergency settings (Bourdinaud and
Pochard, 2003; Chan et al., 2011). Notwithstanding, rapid and
effective pharmacological treatment is often required to ensure
the safety of patients, and caregivers.
Allen (2000) defines agitation as “a temporary disruption of
the typical physician–patient collaboration, which interferes with
assessment and treatment,during a period when immediate assess-
ment and treatment are needed.” Such therapeutic need can be
answered by rapid tranquilization (RT), an approach consisting in
the assertive use of medication to quickly calm severely agitated
patient, decrease dangerous behaviors, and allow treatment of the
underlying condition (Dubin and Feld, 1989; Karagianis et al.,
2001; Mantovani et al., 2010). Therefore, the ultimate goal of RT
is not treating the underlying disorder, but rather reestablishing a
normal physician–patient relation.
Agitation comprises verbal and physical, aggressive and
non-aggressive components. Its hallmarks are motor restless-
ness, heightened responsivity to internal and external stimuli,
irritability, inappropriate or purposeless verbal or motor activity,
in addition with vegetative signs and an unstable course (Lin-
denmayer, 2000). As a consequence, RT may be conceptualized
as initial intervention that cuts across different disorders, being
focused more on acute symptoms than specific diagnosis (De Fruyt
and Demyttenaere, 2004). Behavioral manifestations of agitation
are important therapeutic targets of drug treatment. However,
specific endpoints have not been well defined yet. For example
“sleep” is sometimes considered as a valid treatment target for
agitation reduction, while “tranquillization” (a calming process
different from total sleep induction) has been identified by many
clinicians as the ideal therapeutic endpoint for the treatment of
agitation (Battaglia et al., 2003).
Pharmacological management of agitation in individuals with
psychiatric disorders is under-researched (Alexander et al., 2004).
In particular, RT has not a strong evidence base, with recommen-
dations being partly based on research data, partly on theoretical
considerations and partly on clinical experience (Ferrier, 2006).
The few available guidelines on this topic describe pharmaco-
logical and behavioral interventions of RT in emergency settings
regardless of further diagnostic process.
The need for drug delivery in uncooperative patients favors
the use of intramuscular preparations. Intramuscular treatment
options include BDZ, FGA, and SGA. Each of these medications
offers a unique pharmacological profile that must be considered
when treating agitated patients, who may be unwilling or unable
to adequately communicate their medical status and concomitant
medications (Zimbroff, 2008).
Intramuscular injections of FGA and BDZ, given alone or in
combination, have been the treatment of choice over the past few
decades, with haloperidol and lorazepam being among the most
widely used agents for agitation (Battaglia, 2005).
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Most recent approved guidelines (see Table 1 for details) on
this topic recommend the use of SGA, FGA, and BDZ. They
also include recommendations for specific compounds such as
haloperidol, chlorpromazine, diazepam, lorazepam, and midazo-
lam. However, these latter five drugs, according to most recent
evidences, have questionable tolerability profiles. In particular,
there are growing evidences indicating that haloperidol is involved
in a potentially lethal cardiac arrhythmias named “torsade de
pointe.”This finding led European drug authorities to issue a black
box warning. After that a prolongation of QTc interval in ECG of
some individuals treated with haloperidol was related with fatal
torsades de pointes the use of this drug became strictly regulated,
especially in its parenteral formulation (Hunt and Stern, 1995;
Jackson et al., 1997; Tisdale et al., 2001; Hassaballa and Balk, 2003;
Meyer-Massetti et al., 2010).
Diazepam and midazolam administration bear a strong respi-
ratory function depression risk, especially in patients with condi-
tions limiting respiratory functions, or BDZ metabolism (hepatic
impairment or alcohol abuse) (Denaut et al., 1974/1975; Jedeikin
et al., 1985; Altose and Hudgel, 1986; Peppers, 1996; Nordt and
Clark, 1997; Brice et al., 2003; Arcangeli et al., 2005; Boomsma
et al., 2006). Lorazepam infusion has also been involved in cases of
renal glycol toxicity, especially in patients with substance use (i.e.,
cocaine) (Cawley, 2001; Arcangeli et al., 2005; Wilson et al., 2005;
Zar et al., 2007; Riker and Fraser, 2009).
Another example of the discrepancies between what claimed
in most recent guidelines and what reported in the literature is
the case of chlorpromazine. Several articles, in fact, report an
association of this compound with a high risk of cardiovascu-
lar complications, in particular severe hypotension, given the high
doses required for RT (Fruensgaard, 1978; Hoehns et al., 2001; Wil-
son et al., 2005; Ahmed et al., 2010; Muench and Hamer, 2010).
From this perspective, it is difficult to understand why guide-
lines still recommend parenteral use of BDZ, chlorpromazine, and
haloperidol for RT despite these important safety concerns.
The purpose of this work was to assess a series of guidelines
pharmacological recommendations about RT specifically focusing
on safety issues. We tried to evaluate safety considerations with
particular reference to the use of haloperidol, chlorpromazine,
diazepam, lorazepam, and midazolam.
METHOD
In this paper we reviewed guidelines published from 2000 to 2010
including recommendations about pharmacological treatment
of agitation (see Allen’s definition 3) in psychiatric emergency
settings.
With this purpose, a computerized search for guidelines was
conducted using “PUBMED.” Medical subject heading terms used
for our search were: “agitation,” “acute agitation,” “psychomotor
agitation,”“behavioral agitation,”and each of these terms was com-
bined (by Boolean operator AND), combined with each of the fol-
lowing terms, as medical subject headings:“rapid tranquillization,”
“tranquillization,” “treatment,” “drug treatment,” “pharmacolog-
ical treatment,” “management.” Data resulting from computer
searches were integrated with available published guidelines.
The search was initially restricted to guidelines as publication
type and keyword. No randomized controlled studies or clinical
studies were considered eligible for this particular data selection.
Guidelines were selected and assessed as for drug suggestions and
safety considerations. We focused exclusively on safety issues that
may endanger the patient undergoing parenteral treatment in
emergency setting.
We performed a new computerized search for articles pertain-
ing the safety profile of some of the compounds suggested in guide-
lines for RT of agitated patients (i.e., haloperidol, chlorpromazine,
diazepam, lorazepam, midazolam, olanzapine, aripiprazole, and
ziprasidone). The choice of drugs included in our new search were
based on the following criteria: their belonging to FGAs, BDZ,
or SGAs pharmacologic class, being widely used in emergency
settings, being available in intramuscular formulations. This com-
puterized search for articles was conducted using “PUBMED” by
searching for medical heading terms:“tolerability,”“adverse effect,”
“adverse reaction,” “fatality,” “side effect,” “risk,” combining these
terms with the Boolean operator“AND,”and then combining them
with each of the above mentioned compounds. In this data selec-
tion, we extended our search to reviews and randomized controlled
trials with no restriction to a specific medical condition.
After a revision of collected data pertaining the safety profile
of all of the selected compounds we listed the main safety issues
related to each of them, compared the results of our search, and
then we tried to provide some considerations.
GUIDELINES IN DETAIL
In the “Rationale and guidelines for inpatient treatment of acute
psychosis,” Feifel clearly suggested SGAs as first-line treatment,
while pointing out that competitor-controlled studies of SGA effi-
cacy still consider haloperidol as “. . .gold standard treatment. . .”
Lorazepam (or comparable BDZ) was suggested as a possible
augmentation therapy. No particular mention of arrhythmia or
hypotension risk with FGAs was reported and neither was the risk
of respiratory depression with high potency BDZ (Feifel, 2000).
Grunze et al. (2003) reported that recommended SGAs dosages for
schizophrenia may be too low for controlling agitation in severe
mania and that the efficacy of SGAs in comparison with FGAs
needs to be confirmed by further studies. The same authors rec-
ommend to restrict the prescription of parenteral high doses of
FGAs to very severe or violent cases of mania. On the safety side,
authors state that, for a variety of antipsychotics, prolongation
of the QT interval may constitute a minor additional problem
(Grunze et al., 2003).
A different approach to short-term management of agitation is
adopted by Allen et al. (2001). These authors suggest to take into
account provisional diagnosis (for instance, schizophrenia, mania,
psychotic depression) in drug treatment intervention. Parenteral
injection of a high potency FGA in association with a BDZ is
indicated as the treatment of choice in non-collaborative patients.
However oral BDZ and SGAs should be preferred in all other
cases. As for the safety profile, we found no mention of respiratory
depression risk, and the role of BDZ in alcohol intoxication is far
from being clear: on one side there is lack of consensus among
authors on BDZ use as a first-line treatment in such condition,
on the other there is no clear distinction between alcohol with-
drawal and intoxication where BDZ are indicated as second-line
treatment (Allen et al., 2001). The same authors undertook a new
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survey in 2005. In this update, BDZ were suggested as first-line
treatment for agitation when no patient data are available. No
single SGA emerges as an alternative to haloperidol.
None of the new SGA parenteral formulations received as much
support as traditional agents (i.m. BDZ, i.m. haloperidol) when no
patient data are available, or the diagnosis includes medical comor-
bidity or state of intoxication. Among suggested FGAs, chlor-
promazine received only third-line ratings. Safety issues report a
warning about severe hypotension associated to chlorpromazine.
It seems noteworthy that haloperidol was suggested, in mono-
therapy, “only in the medically compromised” patients and also
in absence of previous patient information, regardless of specific
medical condition that may further increase cardiovascular risk in
such patients (Allen et al., 2005).
The Scottish Intercollegiate Network Guidelines for the treat-
ment of acute mania (2005) suggested parenteral adminis-
tration of antipsychotics (including haloperidol and chlorpro-
mazine), proposing add-on therapy with BDZ, such as parenteral
lorazepam, for emergency situations where sedation is a prior-
ity. Although the authors suggest the use of parenteral FGAs and
BDZ to obtain sedation, they do not provide considerations about
potential cardiovascular risk with administration of haloperidol or
chlorpromazine and they do not mention respiratory depression
risk related to BDZ use (Ebmeier et al., 2005).
In 2005 World Federation of Societies of Biological Psychia-
try guidelines for acute treatment of schizophrenia the suggested
first-line treatment consisted in SGAs (and, alternatively, low doses
of FGAs), with adjunctive BDZ to relieve distress, insomnia, and
behavioral disturbances secondary to acute psychosis. The authors
suggest “regular and liberal doses of BDZ” without any mention
of respiratory depression risk. Interestingly, these same guidelines
mention the risk of QTc prolongation associated with high doses
of intravenous haloperidol (Falkai et al., 2005).
A further indication of SGAs as first-line treatment for agitation
can be found in 2005 Canadian guidelines for acute mania treat-
ment, where olanzapine, risperidone, quetiapine, aripiprazole,
ziprasidone are recommended as first-line treatment in association
with lithium or divalproate. In these guidelines FGAs (haloperidol
or chlorpromazine) are suggested as third-line treatment in asso-
ciation with mood stabilizers, without any consideration about
the associated cardiovascular or hypotension risk (Yatham et al.,
2005).
The National Clinical Practice Guidelines for acute mania
treatment (Ferrier, 2006) recommend antipsychotic medication
only when the clinical presentation includes psychotic symp-
toms or marked behavioral disturbances. In these cases, SGAs
(aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) in
association with mood stabilizers (valproate or lithium) are sug-
gested as first-line oral treatment; IM administration of lorazepam,
olanzapine, or haloperidol is recommended when RT is needed.
Regarding safety issues, the authors mention respiratory depres-
sion, ataxia, sedation, and falls during BDZ treatment. These
guidelines recommend prompt availability of flumazenil and the
necessity of avoiding concomitant use IM olanzapine and BDZ
within an hour. Beside these safety recommendations, though,
there was no explicit mention of cardiovascular risk of arrhythmia
with IM haloperidol, while risk of QTc prolongation was reported
for droperidol and thioridazine (both withdrawn from market).
Authors specified that there was no RCT evidence for the use of
BDZ in acute mania. The same authors also suggested to avoid
chlorpromazine because of hypotension risk. As for SGAs they
were reported to cause less EPS than FGAs but the authors advise
to be cautious with new agents (Ferrier, 2006).
In a review paper published in the same year, Marder (2006)
assessed psychomotor agitation across different mental illnesses,
with a further proposal of treatment guidelines: once again SGAs
are recommended as first-line treatment, with haloperidol being
considered among available FGAs.
As for safety issues, cardiovascular risk related with antipsy-
chotics is reported with at least controversial statements. On one
side it was reported that all FGAs have the potential to increase the
risk of cardiac arrhythmia with reports of sudden death occur-
ring during RT. On the other hand, the authors pointed out that,
in these deaths, the role played by antipsychotics remains unclear
since most fatalities had multiple probable causative factors.
As to BDZ, IM lorazepam remained the most popular one for
use in agitation. It is interesting to note that midazolam (regardless
of registration issues) was found superior to haloperidol on motor
agitation control with respect to diazepam and chlordiazepoxide.
As for the safety of these drugs, BDZ were not recommended in
patients with conditions that limit pulmonary reserve given the
risk of inducing respiratory depression, ataxia, excessive sedation.
The authors concluded that close monitoring of patients receiv-
ing pharmacotherapy for acute agitation was imperative (Marder,
2006).
In a 2009 update of WFSBP guidelines for treatment of acute
mania SGAs (aripiprazole, risperidone, and ziprasidone) plus
mood stabilizers (valproate) are suggested as first-line treatment.
Among FGAs, haloperidol efficacy is reported across all subtypes
of mania and its use suggested in emergency treatment of severe
mania or in non-responders. For the same conditions treatment
with chlorpromazine is also suggested, pointing out that only one
small placebo-controlled study report its efficacy in acute mania.
No cardiovascular risk related to haloperidol or hypotension risk
related to chlorpromazine is mentioned (Grunze et al., 2009).
In 2009 Maudsley Prescribing Guidelines section on the treat-
ment of acutely disturbed or violent behavior, the authors sug-
gest lorazepam or promethazine (oral or IM) for patients taking
antipsychotic treatment, while SGAs (olanzapine, aripiprazole, IM
or oral, oral risperidone) are considered treatment of choice for
antipsychotic naïve patients. As for safety issues, concomitant use
of two or more antipsychotics should generally be avoided due
to greater QT prolongation risk. For the same reason, antipsy-
chotic mono-therapy is considered mandatory in patients receiv-
ing haloperidol. During haloperidol therapy pre-treatment ECG
is required and haloperidol should be the last drug to be taken
into account, according to authors indications. BDZ should not
be administered in combination with IM olanzapine. The authors
also specify that, during RT, temperature, pulse, blood pressure,
and respiratory rate should be monitored (Taylor et al., 2009).
DISCUSSION
Some limitations of this work must be acknowledged. First, we
have included in our revision the most important and widely
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Table 2 | Safety procedures (required or suggested) to reduce the risk of severe adverse effects during IM treatment of agitation.
Im drug Main risks Reference Compulsory safety procedure Useful safety procedures
Haloperidol Torsade de pointe Meyer-Massetti et al. (2010) Pre-treatment ECG required Post-treatment ECG
Tisdale et al. (2001) No antipsychotic combination Electrolyte balance assessment
Hassaballa and Balk (2003)
Hassaballa and Balk (2003)
Jackson et al. (1997)
No familiar, preceding or ongoing
cardiovascular disorder
No concomitant drug affecting QTc
Tox-screen
Neurological assessment
No concomitant General Medical
Condition affecting QTc
Chlorpromazine Severe hypotension Ahmed et al. (2010) Pressure monitoring Test dose before full dose
Muench and Hamer (2010) Pre-treatment ECG useful
Electrolyte balance assessment
Lorazepam Respiratory depression
(lower)
Gillies et al. (2005)
Riker and Fraser (2009)
No drugs or GMC affecting
respiratory function
Blood test
Check for acidosis / anion gap
Propylene glycol toxicity Cawley (2001) Flumazenil available Check for alcohol intoxication
Wilson et al. (2000)
Zar et al. (2007)
Arcangeli et al. (2005)
Diazepam Respiratory depression
Propylene glycol toxicity
Denaut et al. (1974/1975)
Boomsma et al. (2006)
Arcangeli et al. (2005)
No drugs or General Medical
Condition affecting respiratory
function
Blood test useful
Check for acidosis / anion gap
Check for alcohol intoxication
Brice et al. (2003) Flumazenil available
Peppers (1996)
Zar et al. (2007)
Midazolam Respiratory depression
(high)
Nordt and Clark (1997)
Boomsma et al. (2006)
Huf et al. (2005)
No drugs or general medical
condition affecting respiratory
function
Informed consent (off label)
Blood test useful
Check for alcohol intoxication
Spain et al. (2008) Flumazenil available
Olanzapine Cardiorespiratory
depression in
combination with BDZs
Wilson et al. (2012a)
Wilson et al. (2012b)
Avoid BDZs combination None
Ziprasidone QTc prolongation
(controversial)
None None Pre-treatment ECG
Aripiprazole None None None None
Table 3 | Conditions and safety considerations that should preclude specific drug choice during IM treatment of agitation in emergency settings
due to fatality risk.
Condition Safety consideration Drug to avoid
Alcohol abuse/intoxication Possible respiratory distress BDZs
Opioid intoxication Possible respiratory distress BDZs
General medical condition affecting resp. funct Possible respiratory distress BDZs
General medical condition affecting card. funct Cardiovascular risk FGAs
No informations Possible cardiovascular/Qtc affect. cond. Haloperidol
Impossible assessment of resp. function Possible respiratory distress BDZs
Delirium Possible worsening BDZs
Stimulants intoxication Cardiovascular risk FGAs
Impaired renal function/cocaine Propylene glycol toxicity lorazepam, diazepam
BDZs pre-treatment Cardiorespiratory depression Olanzapine
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Table 4 | Basic pharmacokinetic profile of discussed IM drugs (Goodman et al., 2006; *Smith et al., 1981).
Drug Plasma peak time Elimination pathway Half-life (average) Active metabolites
Haloperidol 20′ Hepatic 24 h Hydroxy-haloperidol
Chlorpromazine 15’ Hepatic 15–30 h 7-Hydroxychlorpromazine chlorpromazine N-oxide (possibile)
Lorazepam 2–6 h Hepatic 10–20 h None
Diazepam 1, 5 h Hepatic, renal 4–6 h Desmethyldiazepam, oxazepam
Midazolam* 24′ Hepatic 1–3 h None
Olanzapine 5-8 h Hepatic 21–54 h None
Ziprasidone 6, 6 h Hepatic 6–8 h S-methyldihydroziprasidone
Aripiprazole 3–5 h Hepatic 75–146 h Dehydroaripiprazole
accepted guidelines, however it is possible that we missed to revise
some of the many available contributions on this topic. Second,
agitation is a heterogeneous concept crossing multiple diagnostic
areas in psychiatry. Therefore, one could argue that specific inter-
ventions should vary according to principal psychiatric diagnosis.
However, we explicitly focused on treatment recommendation for
controlling acute symptoms and behavioral disturbances related
to agitation independently of underlying psychiatric condition.
Even in emergency setting, therapeutic choices should be guided
by an assessment of risk/benefit ratio: therefore, another limita-
tion of our study could be acknowledged in our reviewing only
the risk profiles of guideline-recommended interventions.
The aim of this work was to review guidelines suggestions about
RT of acutely agitated patients in a real world setting where provi-
sional diagnosis are common, severe agitation requires parenteral
treatment, and rapid decisions are needed. With these condi-
tions in mind, we tried to focus on safety issues related to the
application of existing guidelines in order to check if they could
help clinicians to lessen the inherent risk of weighing efficacy
versus safety in a very short time. In such a setting, when pos-
sible, blood samples, urinary drug screening, complete physical
examination should always be performed along with a treat-
ment history in order to assess concomitant medical conditions
or substance abuse.
Given the necessity for immediate treatment in patients suf-
fering from agitation there is a warranted clinical need for very
rapid and well tolerated pharmacological intervention. As a result
treatment suggestions for agitated patients rely heavily on admin-
istration of intramuscular antipsychotics or BDZ. Aside for drugs’
efficacy profiles, clinicians should be aware of the risks related with
the high dosage required.
Taken as a whole, drug treatment guidelines of the agitated
psychiatric patient recommend the use of SGAs as first-line com-
pounds. Among feasible options, the use of FGAs and BDZ is still
recommended (or at least considered) for RT despite the increasing
amount of worrisome data about their safety, with little or no men-
tion of the now well established risk of fatalities related to their
use. On the other hand, we found extensive considerations regard-
ing SGA-associated safety; therefore an a-critical application of
suggestions reported in available guidelines may imply significant
risks for the agitated patients undergoing RT.
The major safety concerns about treatment with SGAs include
metabolic effects (weight gain, hyperglycemia, and hyperlipi-
demia). Notwithstanding, these aspects are not particularly rel-
evant within the framework of acute agitation management.
More complex is the issue of potential arrhythmogenic effects
of antipsychotics.
There are anecdotal reports of QTc prolongation with SGAs.
Furthermore, in a recent study examining cardiovascular effects
after SGA medication overdose, no reports of ventricular dys-
rhythmias (including torsade de pointes) could be clearly attrib-
uted to atypical antipsychotic acute administration (Tan et al.,
2009).
Few reports in small samples of patients undergoing intramus-
cular olanzapine – intramuscular BDZ combination treatment for
agitation seem to indicate lower oxygen saturations especially in
patients with alcohol abuse (Wilson et al., 2012a,b). Furthermore,
we have found limitations in the use of such a combination in the
guidelines examined. There are, therefore, sufficient data to limit
the use of this association in agitated patient. Further studies are
needed to clarify definitively this issue.
As a final remark, we would like to summarize a few basic safety
considerations (Tables 2 and 3), together with some pharmacoki-
netic parameters (Table 4), that we find useful to keep an evidence
based security profile in treatment planning.
Randomized case control studies are urgently needed in
order to solve the questions about safety of patients receiving
pharmacological treatment in psychiatric emergency settings.
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